Importer of Record vs FDA Initial Importer

“Importer of Record” and “FDA Initial Importer” sound similar, but they arise under different regulatory systems and carry different responsibilities. Assigning one role does not automatically assign the other.

The Importer of Record (IoR) is principally a U.S. customs role. The IoR is responsible for using reasonable care when making entry, including the accuracy of the declared importer, tariff classification, customs value, country of origin, and applicable duties. A licensed customs broker may prepare and transmit the entry, but the broker does not ordinarily assume the IoR’s underlying responsibility for the information submitted. Merely naming a hospital, clinical site, or other recipient on shipping documents does not make that organization the IoR.

Don’t Assume the Customer Is the Importer of Record

This becomes a significant issue when a foreign manufacturer wants to ship investigational devices directly to clinical sites or, after obtaining U.S. marketing authorization, ship commercial devices directly to hospitals, ambulatory surgery centers, or other customers. The manufacturer may assume that the recipient will clear the shipment as IoR. However, some healthcare systems, universities, and clinical sites expressly prohibit their facilities from acting in that capacity. Others will consider it only after advance review by procurement, legal, tax, customs, or research-administration personnel.

Acting as IoR creates customs, financial, and recordkeeping obligations that many recipients are unwilling or unauthorized to accept. Agreeing to purchase, study, or use a device does not mean that the organization has agreed to assume responsibility for its importation.

The FDA Initial Importer Explained

The FDA Initial Importer is a separate medical-device establishment role. It is generally the U.S. importer that furthers the marketing of a device from a foreign manufacturer toward the person making final delivery or sale to the ultimate consumer or user, without repackaging or otherwise changing the device or its labeling. The Initial Importer must have a staffed physical address in the United States and register its establishment with FDA.

Its responsibilities continue after customs clearance and may include complaint handling, Medical Device Reporting, reports of corrections and removals, device tracking, recall management, recordkeeping, and coordination with the foreign manufacturer.

Even where a hospital or other customer agrees to act as IoR, it does not automatically become the FDA Initial Importer. In a direct-to-end-user model, the recipient may not be furthering the marketing of the device at all. The FDA role must therefore be analyzed separately rather than inferred from the customs entry, invoice terms, consignee designation, or delivery address.

Investigational shipments require additional planning because the importing party, study sponsor, clinical site, and other U.S. participants may have different customs, FDA, and contractual responsibilities. Direct delivery to an investigator or clinical site does not eliminate the need to assign those responsibilities before shipment.

Both roles should therefore be assigned deliberately in the relevant clinical-study agreement, distribution agreement, purchase terms, commercial invoice instructions, customs-broker documentation, and operating procedures.

MDD Options can serve as the designated Importer of Record and FDA Initial Importer, receive inventory at its U.S. depot, and manage domestic distribution to hospitals, ambulatory surgery centers, distributors, and other authorized customers. The same infrastructure can also support the earlier clinical-investigation phase through controlled importation, receipt, storage, and distribution of investigational devices to study sites. In both phases, the foreign manufacturer has a defined U.S. operating partner rather than relying on clinical sites or commercial customers to accept import responsibilities.